The Proliferation and Stemness of Peripheral Blood-Derived Mesenchymal Stromal Cells Were Enhanced by Hypoxia
Overview
Authors
Affiliations
This study aimed to address the dilemma of low peripheral blood-derived mesenchymal stromal cell (PBMSC) activity and reduced phenotype in bone or cartilage tissue engineering. Rat PBMSCs (rPBMSCs) were obtained by density gradient centrifugation, and stromal cell characteristics were confirmed by flow cytometry (FCM) and multi-differentiation potential induction experiments. Cell growth curve, viability experiments, and clone formation experiments were performed by [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) and cell counting, and the cell cycle was confirmed by cell FCM. The proliferation signal pathway and stemness-related proteins were detected by molecular methods including Western blot and real-time polymerase chain reaction. , and were highly expressed, and , and were barely expressed in rPBMSCs. rPBMSCs possessed the potential to differentiate into chondrocytes, adipocytes, and osteoblasts under their respective induction conditions. Cell growth curve and viability experiments were performed under hypoxic conditions: 19% O, 5% O, and 1% O. Specifically, 5% O accelerated the proliferation and expression of the stemness of PBMSCs. Cycle experiments proved that hypoxia promoted the cell transition from the G1 phase to the S phase. Molecular experiments confirmed that 5% O hypoxia significantly elevated the expressions of hypoxia-inducible factor 1α and β-catenin and simultaneously the expressions of cycle-related genes including and stemness-related genes including and . The appropriate concentration of hypoxia (i.e., 5% O) enhanced the proliferation and stemness of rPBMSCs and increased the multidirectional differentiation potential of stromal cells. The proposed culture method could improve the viability and maintain the phenotype of rPBMSCs in cartilage or bone tissue engineering.
Regional Gene Therapy for Bone Tissue Engineering: A Current Concepts Review.
Gallo M, Elias A, Reynolds J, Ball J, Lieberman J Bioengineering (Basel). 2025; 12(2).
PMID: 40001640 PMC: 11852166. DOI: 10.3390/bioengineering12020120.
The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review.
cesnik A, Svajger U Front Cell Dev Biol. 2024; 12:1400347.
PMID: 39129786 PMC: 11310176. DOI: 10.3389/fcell.2024.1400347.
Application progress of single-cell sequencing technology in mesenchymal stem cells research.
Li H, Wang Y, Zhu G, Ma Q, Huang S, Guo G Front Cell Dev Biol. 2024; 11:1336482.
PMID: 38264356 PMC: 10803637. DOI: 10.3389/fcell.2023.1336482.
Regulation Mechanisms and Maintenance Strategies of Stemness in Mesenchymal Stem Cells.
Jiang N, Tian X, Wang Q, Hao J, Jiang J, Wang H Stem Cell Rev Rep. 2023; 20(2):455-483.
PMID: 38010581 DOI: 10.1007/s12015-023-10658-3.
Chen W, Wu P, Yu F, Luo G, Qing L, Tang J Cells. 2022; 11(22).
PMID: 36428981 PMC: 9688488. DOI: 10.3390/cells11223552.